Key Takeaways

• Conneqt Health (ASX:CQT) sold a record 3,574 CONNEQT Pulse units in the June 2026 quarter, up 33% quarter-on-quarter.

• Consumer revenue reached about A$1.3 million, up 21% (34% in constant currency), while digital purchases grew 71% to add recurring income.

• Cumulative clinical subscription annual recurring revenue rose about 70% to roughly A$94,200, with seven new clinical agreements signed in the quarter.

• The company is shifting from a hardware-led model toward higher-margin software, data and subscription revenue built on its SphygmoCor vascular-biomarker technology.

• Investors should watch subscription attach rates, cash burn and funding, and whether new distribution channels such as Blueprint's marketplace scale.

Conneqt Health (ASX:CQT) has reported the strongest quarter yet for its flagship CONNEQT Pulse arterial-health monitor, selling a record number of devices in the three months to 30 June 2026 while the recurring, software-driven part of its business grew even faster. For a company that only launched the consumer product at the start of 2025, the June quarter marks another step in its shift from a legacy medical-device maker into a digital-health platform.

The Sydney-based group, which rebranded from CardieX Limited to Conneqt Health in September 2025, sold 3,574 Pulse units during the quarter, a 33% increase on the prior three months. Just as significantly, it pointed to rapid growth in the digital purchases, subscriptions and clinical agreements that sit on top of each sale — the recurring revenue streams management has described as the real prize.

What Has Happened

In its June 2026 quarterly activities report, Conneqt Health disclosed a series of records across its consumer and clinical operations. The headline was Pulse unit sales of 3,574 for the quarter, up 33% on the March quarter and the highest quarterly total since the device went on sale in January 2025.

Consumer revenue reached approximately A$1.3 million, up 21% quarter-on-quarter, or 34% in constant currency, given much of the revenue is earned in US dollars. Digital purchases grew 71% over the quarter and contributed roughly A$68,000 of recurring revenue, lifting the digital share of total consumer purchases from about 4% to 5%.

On the clinical side, Conneqt signed seven new clinical agreements, adding around A$38,800 of new annual recurring revenue (ARR) with a total contract value of about A$64,500. Cumulative clinical subscription ARR rose roughly 70% to approximately A$94,200, while cumulative contract value climbed about 65% to around A$163,800. The Pulse was also recognised as a leading advanced blood-pressure monitor for 2026 by a US consumer-health body, and selected for inclusion in Blueprint's Protocol Marketplace ahead of an August launch.

Why It Matters

The reason these numbers matter is not the absolute dollars — they remain modest — but the direction of travel. Conneqt is moving away from a business where value is created one device at a time, toward one where each device seeds recurring, higher-margin income from reports, subscriptions and clinical services.

Recurring revenue is prized because it is more predictable, tends to carry higher margins than hardware, and compounds as the installed base grows. The June quarter matters precisely because the recurring lines — digital purchases up 71% and clinical ARR up around 70% — grew faster than device sales themselves. If that pattern holds, Conneqt's revenue mix should gradually tilt toward the software and data side management is targeting.

It is worth being clear-eyed: recurring revenue is still a small slice of the total. Digital income made up only around 5% of consumer purchases, and clinical ARR remains under six figures. The trend is encouraging, but Conneqt is early in proving its subscription economics at scale.

Inside Conneqt Health and the CONNEQT Pulse

Conneqt Health traces its roots to ATCOR and the SphygmoCor platform, a vascular-biomarker technology first commercialised in the 1990s and long used in clinical research. SphygmoCor measures central aortic pressure and arterial stiffness — indicators of vascular health beyond a standard cuff blood-pressure reading — and that clinical heritage underpins the company's newer consumer ambitions.

The CONNEQT Pulse brings a version of this measurement to individuals managing hypertension and cardiovascular risk. Launched in January 2025, it has sold in the United States at price points between roughly US$249 and US$289. Around the hardware, Conneqt has built paid digital features, including its Care+ subscription (about US$199 a year or US$24.99 a month) and pay-as-you-go report bundles, plus an enterprise offering that charges clinics per assessment.

From Hardware to a Data Platform

Management, led by chief executive Craig Cooper, has framed the strategy as a transition "from a hardware-led model towards a software and data-driven revenue platform." The Pulse is the entry point: once a consumer or clinic owns the device, Conneqt can layer on analytics, wearable integrations and clinician-supported telehealth features. The clinical business targets cardiology and family-practice clinics, where recurring per-report fees accumulate across thousands of assessments a year at larger sites.

Key Financial and Operational Details

For Conneqt Health (ASX:CQT), the June quarter builds on momentum evident earlier in the financial year. In the December 2025 quarter, the company reported Pulse revenue above A$1.1 million and cash receipts of A$1.64 million, up 96% quarter-on-quarter, while closing with about A$2.43 million in cash. That quarter also saw a A$3.1 million institutional placement and a A$1.63 million R&D tax refund, underscoring how reliant the group has been on capital markets and government incentives to fund its growth.

As an early-commercialisation company, Conneqt has been running a meaningful operating cash burn as it invests in marketing, product development and staff to scale the Pulse — net operating cash outflow was around A$1.89 million in the December quarter. Investors should watch cash receipts against that burn, the closing balance, and any commentary on financing, as these determine how much runway remains before a further raise. Conneqt's largest shareholder is C2 Ventures, associated with directors Niall Cairns and Craig Cooper — a sign of insider alignment, but also a reminder of the concentrated register typical of micro-cap stocks.

Potential Catalysts

Several developments could act as catalysts. The most direct is continued acceleration in recurring revenue: a rising subscription attach rate, higher subscriber retention and growth in clinical ARR would all reinforce the platform thesis. The Blueprint marketplace listing and the pilot to integrate the device into a national primary-care platform's health stations could widen the funnel. Further agreements with larger cardiology or primary-care networks would lift consumption-based revenue, while any move toward cash-flow breakeven would be welcomed.

Material Risks and Uncertainties

The risks are equally clear. Conneqt remains an early-stage, cash-consuming business, and there is no guarantee its recurring-revenue model reaches the scale needed to fund operations without further capital raisings that could dilute shareholders. Recurring revenue, while growing quickly in percentage terms, is still a small part of the total, and rapid growth off a low base can be hard to sustain.

The business is heavily exposed to the US consumer market and the US-dollar exchange rate, so demand softness or currency moves could pressure reported revenue. Consumer hardware is competitive and marketing-intensive; the sharp rise in advertising spend in earlier quarters shows how much investment is required to drive unit sales. Clinical adoption depends on procurement and reimbursement dynamics outside the company's control. As with any micro-cap, the shares can be volatile and liquidity thin.

What Investors Should Watch Next

For Conneqt Health (ASX:CQT), the near-term signposts are straightforward. Watch the subscription and digital attach rate — the proportion of Pulse buyers who take Care+ or buy report bundles — and subscriber retention, as these drive the recurring mix. Monitor clinical ARR and the pace of new agreements to gauge whether the enterprise channel is gaining traction.

Keep a close eye on the cash position: quarterly receipts versus operating burn, the closing balance, and any signals about financing or a path toward breakeven. Finally, track whether newer channels — the Blueprint marketplace and the health-station pilot — convert into measurable unit and subscription volumes, showing the June-quarter records were the start of a durable trend rather than a seasonal high point.